How two pigmentation variants (IRF4 rs12203592 and SLC45A2 rs16891982) relate to freckling and sun sensitivity, what they do and do not say about melanoma and skin cancer risk, and why early detection matters most.
Solid lines are connections this site curates. Dashed lines mean the two ends share a research paper — worth knowing, and not a claim that one explains the other.
Skin, hair and eye color all come down to one pigment family: melanin, made by cells called melanocytes. There are two chemically distinct forms. Eumelanin is brown-black, and besides giving skin and hair their darker shades, it physically absorbs and scatters ultraviolet (UV) light, acting as a built-in sunshade. Pheomelanin is red-yellow, gives red or blond hair its color, and does essentially none of that UV-blocking work — it may even contribute to UV-related damage. Which pigment a person's melanocytes mostly produce is directed by a molecular switch, and a whole set of genes influences where that switch sits. People whose melanocytes lean toward eumelanin tend to have skin that tans; people who lean toward pheomelanin tend to have skin that burns rather than tans, along with a higher tendency to freckle. That single biological fact — how much of your skin's natural sun protection is being manufactured — is the thread connecting pigmentation genetics to sun sensitivity and, from there, to skin cancer risk.
This page covers two variants that our reports link to that story: rs12203592, near the IRF4 gene, and rs16891982, in the SLC45A2 gene. Both have been studied repeatedly and independently, and both show real, replicated associations — but each tells only part of the pigmentation story, and neither is a skin cancer test.
IRF4 sits near genes that help control pigment production, and rs12203592 is one of the most consistently replicated markers in this whole field. In a large genetic study of people of mostly European descent in the US and Australia, this single variant was strongly associated with hair color, skin color, eye color, and how skin tans in response to sunlight. In a separate study following Australian, British and Swedish twins and families over time, the same variant was linked to freckling scores and to the number and type of moles a person develops, with the pattern shifting somewhat between adolescence and adulthood. Put simply: this is a genuine, well-replicated freckling-and-sun-sensitivity marker, not a single-study curiosity.
SLC45A2 encodes a transporter that melanocytes need to build melanin properly, and rs16891982 is one of the single biggest genetic contributors to the visible skin-color difference between people of recent European ancestry and people of recent African, East Asian or South Asian ancestry. Population genetic databases show the G allele carried on the overwhelming majority of chromosomes in European-ancestry samples, while the C allele predominates in East Asian, South Asian and African-ancestry samples (confirmed directly against Ensembl GRCh38, forward strand, matching the direction already used in this variant's own genotype notes) — among the largest such population contrasts documented anywhere in the pigmentation genome. That makes it a strong marker of lighter overall pigmentation in people of European descent, though (like all such markers) it is only one contributor among several genes that together determine someone's skin tone.
Any honest discussion of freckling and sun sensitivity has to name the gene most responsible for the "classic" red hair, fair skin, easily-burning phenotype: MC1R. Variants in MC1R are the strongest known genetic drivers of red hair, poor tanning ability and sun sensitivity, and they are not among the two headline markers (IRF4 and SLC45A2) this section's personal-report guidance is built around — though one MC1R variant, from a separate skin-cancer sub-analysis, is catalogued elsewhere on this page. That means a result on these two markers alone is partial information — someone could carry MC1R variants that strongly affect their sun sensitivity while showing an unremarkable result on IRF4 and SLC45A2, or vice versa. If you burn easily, freckle heavily, or have red or strawberry-blond hair, treat that observable reality as more informative than either of these two variants individually.
This is the part worth reading carefully, because it is where genuine prevention lives. Both variants discussed here show statistically real associations with melanoma risk in published studies — but the size of that effect is modest. In one combined analysis of melanoma cases and controls from Australia, the UK and Sweden, the IRF4-region variant shifted melanoma odds by roughly 15% overall (somewhat more for melanomas on the trunk), a real but small effect next to the biggest risk drivers, which are:
Fair skin, light eyes, red or blond hair and heavy freckling are themselves markers of higher average risk — but they are markers of the same underlying pigmentation biology these gene variants only partly capture, not a separate genetic risk score layered on top. A person with a "high sun-sensitivity" result on this report is not guaranteed to develop skin cancer, and a person with a "low sun-sensitivity" result is not guaranteed to avoid it.
This deserves to be stated without hedging, because getting it wrong can delay a real diagnosis: people with darker skin tones absolutely can develop melanoma, basal cell carcinoma and squamous cell carcinoma. It happens less often on average, but when it does happen, it is frequently found later, in body sites people don't associate with sun damage — palms, soles, nail beds, and mucous membranes — and outcomes tend to be worse, in real part because of that delay in recognition and diagnosis. Nobody should treat darker natural pigmentation, or a "lower risk" pigmentation-gene result, as a reason to skip skin checks or ignore a changing mole.
Visconti et al. 2018 set out to study something else entirely — the genetics of ease of skin tanning, in 176,678 people of European ancestry. That main analysis found 20 loci significantly associated with tanning ability — 6 confirming earlier findings and 14 novel, 10 of which had never before been linked to any pigmentation trait at all. Thirty-three of this page's variants come from that main result, including well-established pigmentation genes such as OCA2, TYRP1, and KITLG. And along the way, the same study ran a separate non-melanoma skin cancer (NMSC) analysis in the UK Biobank, finding a real genetic correlation between tanning ability and NMSC risk. Thirteen variants from that analysis are on this page — not five, once the rest of the GWAS Catalog record for this same NMSC sub-analysis is accounted for. The five described in earlier updates to this page: rs3900053, in TYR — the core pigmentation gene tyrosinase, already discussed above; rs56238684, near PIGU by nearest-gene distance, though the same position is separately associated with basal cell carcinoma and an extremely strong effect on suntan ability, suggesting it tags a major pigmentation locus rather than a PIGU-specific effect; rs62209647, near CHMP4B, also linked to squamous cell carcinoma specifically; rs62211621, in NCOA6; and rs369805468, near CBFA2T3, right at the genome-wide significance threshold. The eight more: rs12925026, itself in MC1R — worth flagging directly, since this page elsewhere describes MC1R as outside its scope; that statement is about the two headline markers this page's personal-report guidance is built around, not this page's full variant catalogue — plus rs6709352 in THNSL2, rs10202963 near TRAK2, rs111930714 in ZNF341, rs138420351 in DNAH2, rs16982256 in FAM49A, rs17431641 in ZFHX4, and rs2424952 in BPIFB4.
Because melanoma is far more treatable the earlier it's caught, dermatologists teach a simple self-exam checklist, the ABCDE rule, for spotting a mole or spot that deserves professional evaluation:
Any new spot, or a spot that is changing, is worth a dermatologist's attention regardless of genetic background. The payoff for catching melanoma early is enormous: cancer confined to the skin at diagnosis has a dramatically better outlook than melanoma that has spread to distant organs. That gap is the single biggest reason regular skin self-checks and periodic professional exams matter — far more than any one gene variant, including the two described here.
Positions joined since this page was written
What this is The text above discusses the variants this page was written around. Since then the catalogue has joined 19 more positions to it, by shared trait or shared paper. They are listed here by the paper each came from; the text does not describe them, and each variant page carries that study's own record.
Verma A et al. 2024, Science (New York, N.Y.) rs35480566 (FOXP1), rs9549316 (ATP11A), rs113663016 (RCC2), rs114420104 (HLA-DQA1), rs79643549 (near GACAT3), rs55716899 (FOXP1), rs10905480 (LINC02676), rs112840089 (ZFHX4-AS1), rs10962650 (near BNC2), rs78267753 (LINC02676), rs9265142 (near LINC02571), rs16897870 (RGS22) — PMID:39024449
Sakaue S et al. 2021, Nature genetics rs77100309 (JDP2), rs10859996 (HAL), rs553341619 (SHANK2), rs113394050 (RGS22), rs201601284 (CEP43), rs6444285 (LPP), rs200167108 (PRP4K) — PMID:34594039
2026-01-01 · Genome-wide association study reveals genetic architecture and evolution of human retinal pigmentation. Science Advances. 2026. DOI:10.1126/sciadv.adw7768
Retinal pigmentation -- how much melanin lines the back of the eye, protecting it from light-induced damage -- had not been studied at genome-wide scale, largely for lack of a way to quantify it from routine eye photos. This study built a deep learning tool (DeepGRP) to score retinal pigmentation from fundus images, then ran a GWAS finding 42 signals, 26 of them newly identified, with SNP-based heritability of 21.4%. Single-cell chromatin and RNA sequencing of human fetal retinal tissue pointed to retinal pigment epithelium and photoreceptor cells as the key cell types involved, and identified ARHGAP18 as a previously unrecognized regulator of melanin production (melanogenesis). The study found evidence of polygenic adaptation specifically in Europeans, consistent with selection pressure from snow-reflected light at high latitudes -- a genuine evolutionary genetics finding, not just a disease-risk one. Most practically, a polygenic score for retinal pigmentation correlated with a 4.8-fold higher risk of myopia and, in the opposite direction, a 1.5-fold lower risk of skin cancer -- a real genetic tradeoff between two very different outcomes tied to the same pigmentation biology. This site's eye color and pigmentation page carries just 4 variants; ARHGAP18 and the other 41 signals are not currently among them. Given the skin cancer connection, this site's sun sensitivity and skin cancer risk page is also a genuine match.
Human pigmentation is produced by melanocytes, which synthesize two chemically distinct melanin polymers: eumelanin (brown-black, photoprotective, absorbing and scattering UV radiation) and pheomelanin (red-yellow, largely non-photoprotective and possibly pro-oxidant under UV exposure). The eumelanin/pheomelanin ratio is governed principally by melanocortin 1 receptor (MC1R) signaling — receptor activation favors eumelanogenesis, while low activation favors pheomelanogenesis — but is modulated by numerous additional loci affecting melanocyte development, melanosome trafficking and tyrosinase pathway activity. Both genes discussed here act within that broader pathway rather than at the MC1R switch itself.
rs12203592 is an intronic SNP at chromosome 6p25.3, mapped to IRF4 (interferon regulatory factor 4; also near DUSP22 and EXOC2), acting via a regulatory effect on IRF4 expression in melanocytes rather than an amino-acid change. In a genome-wide association study of predominantly European-ancestry participants in the United States and Australia (Han et al., PLoS Genetics 2008, PMID 18483556), this variant showed genome-wide-significant association with hair color (p = 7.46 × 10-127), skin color (p = 6.2 × 10-14), eye color (p = 6.1 × 10-13) and tanning response to sunlight (p = 3.9 × 10-89). In Australian, UK and Swedish twin/family cohorts (Duffy et al., American Journal of Human Genetics 2010, PMID 20602913), the rs12203592*T allele was associated with higher freckling scores and higher nevus counts in adolescents (though with lower nevus counts and persistently high freckling scores in adults, indicating a genotype-by-age interaction); the opposite (*C) allele showed a modest association with melanoma in combined case-control analysis (OR 1.15, p = 4 × 10-3; OR 1.33, p = 2.5 × 10-5 for trunk melanoma specifically), corroborated in an independent GenoMEL consortium GWAS at an adjacent SNP. Per gnomAD, the minor (T) allele frequency is approximately 17% in non-Finnish Europeans and 21% in Ashkenazi Jewish samples, versus approximately 3% in African, roughly 1% in South Asian, and under 0.1% in East Asian reference populations.
rs16891982 is a missense variant (c.1122C>G; p.Phe374Leu / L374F nomenclature; also known as MATP L374F) in SLC45A2, encoding a melanosomal membrane transporter required for normal melanin synthesis. It is among the pigmentation variants with the largest documented allele-frequency contrast between continental population groups: per Ensembl/gnomAD population data, the allele common in Europeans is carried on approximately 97% of non-Finnish European chromosomes, versus approximately 13% of African, 10% of South Asian, and under 1% of East Asian chromosomes sampled — among the sharpest population-frequency gradients of any pigmentation locus, and a marker widely used in forensic ancestry-informative panels. In a Spanish case-control study (131 melanoma cases, 245 controls; Fernandez et al., Human Mutation 2008, PMID 18563784), the variant allele associated with darker pigmentation was protective against melanoma relative to the allele common in Europeans (OR 0.41), the first report establishing SLC45A2 as a melanoma-susceptibility locus in a light-skinned population; replication in additional cohorts and populations has been more limited than for IRF4/MC1R, so this effect size should be treated as suggestive of a real but population-specific-magnitude association rather than a precisely fixed universal risk figure.
MC1R (chromosome 16q24.3) is the best-characterized locus for red hair, sun sensitivity and freckling, with multiple loss-of-function variants (e.g., R151C, R160W, D294H) each individually conferring substantially larger effects on the eumelanin/pheomelanin ratio than either variant above; MC1R genotype is not included in this report, so this page addresses only a partial slice of the polygenic sun-sensitivity/pigmentation architecture.
Per National Cancer Institute risk-factor summaries, established melanoma risk factors, roughly in order of individual contribution, include: dysplastic nevus and/or high total nevus count, cumulative and intermittent-intense UV exposure (including indoor tanning device use), history of severe blistering sunburn (childhood exposure carrying particular weight), family history (two or more affected first-degree relatives), personal history of prior melanoma, immunosuppression, and constitutional pigmentation phenotype (fair skin, light eyes, red/blond hair, heavy freckling). IRF4 and SLC45A2 genotype contribute to that last, phenotype-level category and should be interpreted as modest, partially overlapping proxies for constitutional pigmentation type rather than independent, additive risk scores. Basal cell and squamous cell carcinoma share UV exposure and fair pigmentation as major risk factors, but neither variant discussed here has comparably robust, replicated, variant-specific effect-size data for keratinocyte carcinomas as exists for melanoma; the association for these two markers is best characterized as a melanoma- and general-pigmentation-level finding.
Per the American Academy of Dermatology, skin cancer (including melanoma) in patients with darker skin tones is often diagnosed at a later stage, frequently at atypical anatomic sites (palms, soles, nail beds, mucosal surfaces) not classically associated with UV exposure, and patients with darker skin tones have lower melanoma survival than patients with lighter skin tones — a disparity attributed substantially to delayed recognition and diagnosis rather than to an absence of risk.
The ABCDE criteria (Asymmetry, Border irregularity, Color variegation, Diameter greater than approximately 6 mm, Evolution/change over time), taught by the American Academy of Dermatology, the American Cancer Society and the National Cancer Institute alike, remain the standard patient- and clinician-facing screening heuristic for pigmented lesion evaluation, with any new or changing lesion warranting evaluation regardless of ABCDE status. Per American Cancer Society SEER-based survival statistics for melanoma diagnosed 2015-2021, 5-year relative survival is greater than 99% for localized disease, 76% for regional (nodal) spread, and 36% for distant metastatic disease, illustrating the outsized clinical value of early detection relative to any single genetic risk marker.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Sun Sensitivity, Freckling and Skin Cancer Risk comes down to these specific, well-studied positions — not a diagnosis. 70 positions are linked to this page; the ones this page's own text discusses are shown first.
The studies behind these variants recruited participants from different ancestries — a result found in one population doesn't always transfer to another. Based on 48 of 70 linked studies with a resolved discovery ancestry.
Databases, guidelines and references
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Sun Sensitivity, Freckling and Skin Cancer Risk. MyGeneLog™. https://www.mygenelog.com/conditions/sun-sensitivity-and-skin-cancer-risk
Yes, unambiguously. Melanoma, basal cell carcinoma and squamous cell carcinoma all occur in people with darker skin tones. It happens less often on average, but when it does, it is frequently diagnosed later and at atypical sites such as palms, soles and nail beds that people don't associate with sun damage, and survival tends to be worse partly because of that delay. Darker natural pigmentation lowers average risk; it does not eliminate it, and it is never a reason to skip a skin check or ignore a changing spot.
Not directly. Both have real, replicated associations with pigmentation and sun-sensitivity traits, and IRF4's variant shows a small (roughly 15%) shift in melanoma odds in published studies. But the biggest drivers of skin cancer risk are lifetime UV exposure, sunburn history, mole count, and family history — not this variant pair. Treat a result here as one modest data point about pigmentation biology, not a risk score.
MC1R is the single strongest known genetic driver of red hair, poor tanning and sun sensitivity, and it genuinely is not part of this test. That means someone could carry sun-sensitivity-relevant MC1R variants while showing an unremarkable IRF4/SLC45A2 result, or the reverse. A result on these two markers is a partial picture of pigmentation genetics, not a complete one.
The evidence-backed basics apply to everyone regardless of genotype: limit cumulative and intense UV exposure, avoid indoor tanning devices, treat sunburns (especially in childhood) as something to actively prevent, and get new or changing moles checked using the ABCDE rule (Asymmetry, Border irregularity, Color variation, Diameter over about 6mm, Evolving appearance). People with more moles, a family history of melanoma, or fair pigmentation traits benefit from more frequent professional skin exams.
Because melanoma caught while still confined to the skin has a 5-year relative survival above 99%, versus 76% once it has reached nearby lymph nodes and 36% once it has spread to distant organs (American Cancer Society data). Learning to recognize a mole that is asymmetric, has an irregular border, uneven color, a diameter over about 6mm, or is changing over time is one of the most effective, low-cost things a person can do for their own outcome, regardless of any genetic result.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog™. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.